Colorectal CancerKFTRNCT07923682
Outcomes of Knife-Assisted Full-Thickness Resection for Rectal Lesions: A Multicenter Study
An observational study of Colorectal Cancer, run by University Hospital, Ghent at 1 site in Belgium.
Trial summary
This study looks at the results of a new technique called knife-assisted full-thickness resection (kFTR) for removing rectal lesions. In kFTR, a doctor uses an electrical knife to remove a rectal growth along with the full thickness of the rectal wall. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Colorectal Cancer
- How many people
- 150 participants
- Where
- 1 siteBelgium
- Study dates
- 2 May 2025to 31 Dec 2029
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients who underwent endoscopic knife-assisted full-thickness resection (kFTR) for rectal lesions at participating international centers
Who may be able to join
- Patients aged 18 years and older
- Knife-assisted full-thickness resection (kFTR) performed for a rectal lesion at a participating center
Who cannot join
- Unavailable information regarding kFTR technical outcomes
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Belgium1 site, 1 recruiting
- Recruiting
University Hospital Ghent
Ghent, 9000
David Tate, 093321063, studiestissue.resectie@uzgent.be
About this study
Official title: Outcomes of Endoscopic Knife-Assisted Full-Thickness Resection for Rectal Lesions: An International Multicentre Retrospective Cohort Study
This study looks at the results of a new technique called knife-assisted full-thickness resection (kFTR) for removing rectal lesions. In kFTR, a doctor uses an electrical knife to remove a rectal growth along with the full thickness of the rectal wall. Current methods for removing early rectal tumors each have limits depending on the size and location of the growth. This study collects data from hospitals in multiple countries to find out how well kFTR works and how safe it is. Researchers review medical records and endoscopy reports from patients who already had kFTR at participating hospitals. The main measures are whether the procedure was completed successfully, whether the growth was removed in one piece, whether the edges were cancer-free, and how often complications occurred. The study also tracks hospital stay length, need for additional surgery, cancer recurrence, and death.
Read the detailed description
Background
Minimally invasive, organ-preserving techniques have become the preferred approach for early rectal cancer resection, replacing total mesorectal excision due to its high morbidity (12.1%-13.4%) and mortality (1%-1.5%). Recent meta-analysis data indicate that deep submucosal invasion is not an independent risk factor for lymph node metastasis in colorectal cancer (CRC), with 37.9% of deeply invasive cancers lacking other histologic high-risk features, making them suitable for curative endoscopic resection. However, current endoscopic techniques such as endoscopic submucosal dissection (ESD), Transanal Minimally Invasive Surgery (TAMIS), endoscopic device-assisted full-thickness resection (FTRD), and endoscopic intermuscular dissection (EID) have limitations in specific scenarios.
Endoscopic knife-assisted full-thickness resection (kFTR) has emerged as a novel technique for local excision of rectal lesions but remains under-evaluated in large cohort studies. The objective of this study is to assess the technical and clinical outcomes of kFTR for rectal lesions, including technical success, en-bloc and R0 resection rates, and the incidence of complications.
Study Endpoints
The primary outcomes of this study include technical success, en-bloc resection, and R0 resection rates. Additionally, complications such as intraprocedural and delayed bleeding, post-polypectomy syndrome, and other procedure-related adverse events will be evaluated. Secondary outcomes include the length of hospital stay, the need for adjunctive surgery due to complications or non-curative resections, locoregional or non-salvageable recurrence, and mortality.
Methods
This study follows a retrospective, international, multicenter cohort design. Eligible participants include patients aged 18 years or older who underwent kFTR at the participating centers. Cases with missing data on kFTR technical outcomes are excluded. Due to the limited availability of previous data on rectal kFTR, all eligible cases will be included without a predefined sample size calculation.
Data will be collected from electronic medical records, endoscopic images, and videos. Extracted patient characteristics include age, sex, comorbidities, ASA classification, prior neoadjuvant treatment, and preoperative staging. Lesion characteristics such as size, location, morphology (JNET and Paris classification), previous resection attempts, and fibrosis grade will also be recorded. Procedure-related variables include anesthesia type, dissection technique, defect closure, procedural success, procedural time, complications, and hospital stay. Histopathological data will be analyzed for tumor staging (pT), radicality, and high-risk features for nodal metastasis. Clinical outcomes such as adjuvant therapy, follow-up duration, recurrence, and mortality will be documented.
Variable Definitions
Technical success is defined as the completion of the procedure with lesion removal without conversion to another technique. Procedural time is measured from submucosal injection to procedure completion. Bleeding is classified as intraprocedural (requiring intervention) or delayed (occurring within 30 days post-procedure and necessitating medical intervention). Post-polypectomy syndrome is characterized by abdominal pain within 24 hours of the procedure that resolves with conservative management. Tumor budding is categorized into low (0-4 buds), intermediate (5-9 buds), and high (≥10 buds) groups. Metastases are classified as locoregional (spread to surrounding tissues or regional lymph nodes) or distant (e.g., liver, lung, peritoneum).
Statistical Analysis
Categorical variables will be presented as frequencies and percentages, while continuous variables will be reported as means (standard deviation) or medians (interquartile range), depending on data distribution. Subgroup analyses will assess effectiveness and safety outcomes based on lesion location, size, fibrosis, and resection technique. Comparisons between categorical variables will be conducted using chi-squared or Fisher's exact tests, while t-tests will be used for continuous variables.
Recurrence after resection will be analyzed over time using Kaplan-Meier survival analysis, with log-rank tests applied for group comparisons. Univariable analyses will assess associations between independent variables and key outcomes, including en-bloc resection, recurrence, and complications. Multivariable regression models will incorporate relevant variables to evaluate their independent associations with these outcomes. A p-value of ≤0.05 will be considered statistically significant. All statistical analyses will be performed using R software.
Data Management
Data will be anonymized, with each center maintaining a separate key linking patient identifiers to unique study IDs. Clinical data will be stored securely on UZ Gent servers and retained for 10 years following study completion before being permanently deleted. Access to the data will be restricted to study investigators.
- Conditions
- Colorectal Cancer
- Keywords
- Colorectal Cancer, knife-assisted full-thickness resection, endoscopic resection, early rectal cancer, endoscopic submucosal dissection
- Medical subject headings
- Colorectal Neoplasms, Rectal Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| kFTR Recipients | Patients aged 18 years and older who underwent endoscopic knife-assisted full-thickness resection (kFTR) for rectal lesions at participating international centers, with available data on technical outcomes. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Technical success rate
Proportion of procedures completed with macroscopic lesion removal without conversion to another technique
Measured: At the time of the procedure
En-bloc resection rate
Proportion of lesions removed in a single piece
Measured: At the time of the procedure
R0 resection rate
Proportion of resections with histologically confirmed complete margin-free resection
Measured: Within 2 weeks of the procedure (histopathology report)
Rate of complications
Composite of intraprocedural bleeding (requiring endoscopic treatment), delayed bleeding (requiring hospitalization, ED visit, or endoscopic/angiographic/surgical intervention within 30 days), post-polypectomy syndrome (abdominal pain within 24 hours resolving with conservative management), and other procedure-related complications
Measured: Within 30 days of the procedure
Secondary outcomes (4)
Length of hospital stay
Duration of hospitalization following kFTR, measured in days
Measured: Perioperative (from procedure to hospital discharge, up to 30 days)
Rate of adjunctive surgery
Proportion of patients requiring surgery for complications, failure after endoscopic resection, or non-curative resections
Measured: Through study completion, up to end of follow-up (up to 7 years)
Locoregional or non-salvageable recurrence rate
Proportion of patients with cancer recurrence at or near the resection site, or distant recurrence not amenable to salvage therapy
Measured: Through study completion, up to end of follow-up (up to 7 years)
Mortality
Death from any cause during follow-up
Measured: Through study completion, up to end of follow-up (up to 7 years)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Nov 2026
- Study start2 May 2025
- Primary completion31 Dec 2029 (estimated)
- Study completion31 Dec 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Colorectal CancerStudies of the same condition, open and under way.
- More trials run by University Hospital, GhentThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 150 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital, Ghent
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- David Tate, Principal investigator, University Hospital, Ghent
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07923682
- Sponsor's protocol ID
- ONZ-2025-0215
- Acronym
- KFTR
- Status last verified
- Nov 2026
- First submitted
- 4 Jun 2026
- Last updated
- 6 Nov 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 6 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Outcomes of Endoscopic Knife-Assisted Full-Thickness Resection for Rectal Lesions: An International Multicentre Retrospective Cohort Study
- ClinicalTrials.gov ID
- NCT07923682
- Acronym / sponsor ID
- KFTR / ONZ-2025-0215
- Conditions
- Colorectal Cancer
- Keywords
- Colorectal Cancer, knife-assisted full-thickness resection, endoscopic resection, early rectal cancer, endoscopic submucosal dissection
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 150 participants (estimated)
- Lead sponsor
- University Hospital, GhentUniversity, hospital or other
- Study start
- 2 May 2025 (actual)
- Primary completion
- 31 Dec 2029 (estimated)
- Study completion
- 31 Dec 2029 (estimated)
- First posted
- 6 Nov 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study looks at the results of a new technique called knife-assisted full-thickness resection (kFTR) for removing rectal lesions. In kFTR, a doctor uses an electrical knife to remove a rectal growth along with the full thickness of the rectal wall. Current methods for removing early rectal tumors each have limits depending on the size and location of the growth. This study collects data from hospitals in multiple countries to find out how well kFTR works and how safe it is. Researchers review medical records and endoscopy reports from patients who already had kFTR at participating hospitals. The main measures are whether the procedure was completed successfully, whether the growth was removed in one piece, whether the edges were cancer-free, and how often complications occurred. The study also tracks hospital stay length, need for additional surgery, cancer recurrence, and death.
Detailed description
Background
Minimally invasive, organ-preserving techniques have become the preferred approach for early rectal cancer resection, replacing total mesorectal excision due to its high morbidity (12.1%-13.4%) and mortality (1%-1.5%). Recent meta-analysis data indicate that deep submucosal invasion is not an independent risk factor for lymph node metastasis in colorectal cancer (CRC), with 37.9% of deeply invasive cancers lacking other histologic high-risk features, making them suitable for curative endoscopic resection. However, current endoscopic techniques such as endoscopic submucosal dissection (ESD), Transanal Minimally Invasive Surgery (TAMIS), endoscopic device-assisted full-thickness resection (FTRD), and endoscopic intermuscular dissection (EID) have limitations in specific scenarios.
Endoscopic knife-assisted full-thickness resection (kFTR) has emerged as a novel technique for local excision of rectal lesions but remains under-evaluated in large cohort studies. The objective of this study is to assess the technical and clinical outcomes of kFTR for rectal lesions, including technical success, en-bloc and R0 resection rates, and the incidence of complications.
Study Endpoints
The primary outcomes of this study include technical success, en-bloc resection, and R0 resection rates. Additionally, complications such as intraprocedural and delayed bleeding, post-polypectomy syndrome, and other procedure-related adverse events will be evaluated. Secondary outcomes include the length of hospital stay, the need for adjunctive surgery due to complications or non-curative resections, locoregional or non-salvageable recurrence, and mortality.
Methods
This study follows a retrospective, international, multicenter cohort design. Eligible participants include patients aged 18 years or older who underwent kFTR at the participating centers. Cases with missing data on kFTR technical outcomes are excluded. Due to the limited availability of previous data on rectal kFTR, all eligible cases will be included without a predefined sample size calculation.
Data will be collected from electronic medical records, endoscopic images, and videos. Extracted patient characteristics include age, sex, comorbidities, ASA classification, prior neoadjuvant treatment, and preoperative staging. Lesion characteristics such as size, location, morphology (JNET and Paris classification), previous resection attempts, and fibrosis grade will also be recorded. Procedure-related variables include anesthesia type, dissection technique, defect closure, procedural success, procedural time, complications, and hospital stay. Histopathological data will be analyzed for tumor staging (pT), radicality, and high-risk features for nodal metastasis. Clinical outcomes such as adjuvant therapy, follow-up duration, recurrence, and mortality will be documented.
Variable Definitions
Technical success is defined as the completion of the procedure with lesion removal without conversion to another technique. Procedural time is measured from submucosal injection to procedure completion. Bleeding is classified as intraprocedural (requiring intervention) or delayed (occurring within 30 days post-procedure and necessitating medical intervention). Post-polypectomy syndrome is characterized by abdominal pain within 24 hours of the procedure that resolves with conservative management. Tumor budding is categorized into low (0-4 buds), intermediate (5-9 buds), and high (≥10 buds) groups. Metastases are classified as locoregional (spread to surrounding tissues or regional lymph nodes) or distant (e.g., liver, lung, peritoneum).
Statistical Analysis
Categorical variables will be presented as frequencies and percentages, while continuous variables will be reported as means (standard deviation) or medians (interquartile range), depending on data distribution. Subgroup analyses will assess effectiveness and safety outcomes based on lesion location, size, fibrosis, and resection technique. Comparisons between categorical variables will be conducted using chi-squared or Fisher's exact tests, while t-tests will be used for continuous variables.
Recurrence after resection will be analyzed over time using Kaplan-Meier survival analysis, with log-rank tests applied for group comparisons. Univariable analyses will assess associations between independent variables and key outcomes, including en-bloc resection, recurrence, and complications. Multivariable regression models will incorporate relevant variables to evaluate their independent associations with these outcomes. A p-value of ≤0.05 will be considered statistically significant. All statistical analyses will be performed using R software.
Data Management
Data will be anonymized, with each center maintaining a separate key linking patient identifiers to unique study IDs. Clinical data will be stored securely on UZ Gent servers and retained for 10 years following study completion before being permanently deleted. Access to the data will be restricted to study investigators.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| kFTR Recipients | – | –Patients aged 18 years and older who underwent endoscopic knife-assisted full-thickness resection (kFTR) for rectal lesions at participating international centers, with available data on technical outcomes. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients who underwent endoscopic knife-assisted full-thickness resection (kFTR) for rectal lesions at participating international centers
Key inclusion criteria (2 listed)
- Patients aged 18 years and older
- Knife-assisted full-thickness resection (kFTR) performed for a rectal lesion at a participating center
Key exclusion criteria (1 listed)
- Unavailable information regarding kFTR technical outcomes
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Technical success rate
Time frame: At the time of the procedure
Proportion of procedures completed with macroscopic lesion removal without conversion to another technique
En-bloc resection rate
Time frame: At the time of the procedure
Proportion of lesions removed in a single piece
R0 resection rate
Time frame: Within 2 weeks of the procedure (histopathology report)
Proportion of resections with histologically confirmed complete margin-free resection
Rate of complications
Time frame: Within 30 days of the procedure
Composite of intraprocedural bleeding (requiring endoscopic treatment), delayed bleeding (requiring hospitalization, ED visit, or endoscopic/angiographic/surgical intervention within 30 days), post-polypectomy syndrome (abdominal pain within 24 hours resolving with conservative management), and other procedure-related complications
4 secondary outcomes
Length of hospital stay
Time frame: Perioperative (from procedure to hospital discharge, up to 30 days)
Rate of adjunctive surgery
Time frame: Through study completion, up to end of follow-up (up to 7 years)
Locoregional or non-salvageable recurrence rate
Time frame: Through study completion, up to end of follow-up (up to 7 years)
Mortality
Time frame: Through study completion, up to end of follow-up (up to 7 years)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Nov 2026.
Related trials for Colorectal Cancer
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingObservational study
Pre- and On-treatment Multi-omics Profiling of Locally Advanced Rectal Cancer
Rectal Neoplasms
Enrolling by invitationObservational study
Natural History Study of Early Life Exposures in Agriculture (ELEA)
Prostate Cancer, Leukemia
RecruitingPhase 2
Tislelizumab in People With Colorectal Cancer
Colorectal Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
David Tate principal investigator
University Hospital, Ghent
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Colorectal Cancer, run by University Hospital, Ghent at 1 site in Belgium.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 6 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact David Tate (093321063, studiestissue.resectie@uzgent.be), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Technical success rate (time frame: At the time of the procedure). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Nov 2026.